Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome).
Level 5 - mechanism / opinion, no new human data
Clinical practice guideline / expert consensus position statement without a systematic review methodology described in the abstract.
PubMed 34508691 · doi:10.1016/j.ando.2021.09.001
What was done
This position statement outlines consensus diagnostic criteria, etiological evaluations, and clinical management recommendations for premature/primary ovarian insufficiency (POI), excluding Turner syndrome.
What was found
The guideline reports that POI affects 1% to 2% of women under 40, 1 in 1,000 under 30, and 1 in 10,000 under 20. Over 60% of primary POI cases remain idiopathic despite genetic advancements. Diagnostic criteria require primary or secondary amenorrhea or spaniomenorrhea for >4 months before age 40 and elevated follicle-stimulating hormone (FSH >25 IU/L) on two separate assays at least 4 weeks apart, typically accompanied by low estradiol and collapsed anti-Müllerian hormone (AMH). Spontaneous pregnancy occurs in approximately 6% of cases due to fluctuating ovarian function. Recommended management includes karyotyping, FMR1 screening, gene panels, auto-immune testing, and mandatory hormone replacement therapy up to at least the physiological menopause age of 51 years.
Why it matters
It provides standardized clinical criteria and diagnostic pathways to optimize etiological investigation and endocrine management for non-Turner premature ovarian insufficiency.
Limits
The abstract describes a position statement without detailing systematic review protocols, search strategies, or formal grading of evidence. Primary clinical trial data are not reported.
Cited by
- supports Premature ovarian failure is defined as going into ovarian failure before age 40.